Pentadecanoic acid, a saturated fat in whole dairy fat, is administered orally in purified form for health and longevity. Higher blood levels line up with a modestly lower chance of heart disease and type 2 diabetes, too mixed with diet to show it is protective. Cholesterol fell further and one liver enzyme fell. Liver fat followed the diet. No serious harms were reported over three months. No shown lifespan effect. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Circulating pentadecanoic acid | No established target; track change from the person's own baseline | Shows whether the dose raised the level the trials actually moved |
| LDL cholesterol | <100 mg/dL; <70 mg/dL when artery disease is already a personal priority | The one supplement signal that is a validated cardiovascular surrogate |
| ALT | <25 U/L in women; <33 U/L in men | Liver-enzyme signal was after-the-fact and only above a blood-level line |
| AST | <30 U/L | Second liver enzyme in the same after-the-fact split |
| GGT | <20 U/L | The liver enzyme that fell versus placebo at 12 weeks |
| Hemoglobin | Women 12.5–14.5 g/dL; men 14.0–15.5 g/dL | An after-the-fact rise was reported above the 5 microgram line |
| Fasting glucose | 75–90 mg/dL | Cohorts link the biomarker to diabetes; trials did not move glucose clearly |
| hs-CRP | <1.0 mg/L | Cell work is anti-inflammatory; human trials have not shown a CRP drop |
Cadence: Baseline before oral use; at 12 weeks, then every 6 to 12 months if use continues. Qualitative markers at baseline and each lab visit.